Global C-MET & HGF Inhibitors Industry Growth and Trends Forecast to 2031

Summary

c-Met inhibitors are a class of small molecules that inhibit the enzymatic activity of the c-Met tyrosine kinase, the receptor of hepatocyte growth factor/scatter factor (HGF/SF).

According to APO Research, The global C-MET & HGF Inhibitors market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.

North American market for C-MET & HGF Inhibitors is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Asia-Pacific market for C-MET & HGF Inhibitors is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Europe market for C-MET & HGF Inhibitors is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

The major global manufacturers of C-MET & HGF Inhibitors include Exelixis, Ipsen, Pfizer, Novartis, Takeda, Merck KGaA, Merck, Daiichi Sankyo and GSK, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for C-MET & HGF Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding C-MET & HGF Inhibitors.

The C-MET & HGF Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global C-MET & HGF Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

C-MET & HGF Inhibitors Segment by Company

Exelixis
Ipsen
Pfizer
Novartis
Takeda
Merck KGaA
Merck
Daiichi Sankyo
GSK
Bristol-Myers Squibb(BMS)
Roche
AVEO Pharmaceuticals
Amgen
AstraZeneca
Mirati Therapeutics
Eli Lilly
Johnson & Johnson
Eisai
Hutchison MediPharma
Kringle Pharmaceuticals

C-MET & HGF Inhibitors Segment by Type

Cabozantinib
Crizotinib
Others

C-MET & HGF Inhibitors Segment by Application

Hospital
Drug Store

C-MET & HGF Inhibitors Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global C-MET & HGF Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of C-MET & HGF Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of C-MET & HGF Inhibitors.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of C-MET & HGF Inhibitors manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of C-MET & HGF Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Market Overview

1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global C-MET & HGF Inhibitors Market Size Estimates and Forecasts (2020-2031)
1.2.2 Global C-MET & HGF Inhibitors Sales Estimates and Forecasts (2020-2031)
1.3 C-MET & HGF Inhibitors Market by Type
1.3.1 Cabozantinib
1.3.2 Crizotinib
1.3.3 Others
1.4 Global C-MET & HGF Inhibitors Market Size by Type
1.4.1 Global C-MET & HGF Inhibitors Market Size Overview by Type (2020-2031)
1.4.2 Global C-MET & HGF Inhibitors Historic Market Size Review by Type (2020-2025)
1.4.3 Global C-MET & HGF Inhibitors Forecasted Market Size by Type (2026-2031)
1.5 Key Regions Market Size by Type
1.5.1 North America C-MET & HGF Inhibitors Sales Breakdown by Type (2020-2025)
1.5.2 Europe C-MET & HGF Inhibitors Sales Breakdown by Type (2020-2025)
1.5.3 Asia-Pacific C-MET & HGF Inhibitors Sales Breakdown by Type (2020-2025)
1.5.4 South America C-MET & HGF Inhibitors Sales Breakdown by Type (2020-2025)
1.5.5 Middle East and Africa C-MET & HGF Inhibitors Sales Breakdown by Type (2020-2025)
2 Global Market Dynamics

2.1 C-MET & HGF Inhibitors Industry Trends
2.2 C-MET & HGF Inhibitors Industry Drivers
2.3 C-MET & HGF Inhibitors Industry Opportunities and Challenges
2.4 C-MET & HGF Inhibitors Industry Restraints
3 Market Competitive Landscape by Company

3.1 Global Top Players by C-MET & HGF Inhibitors Revenue (2020-2025)
3.2 Global Top Players by C-MET & HGF Inhibitors Sales (2020-2025)
3.3 Global Top Players by C-MET & HGF Inhibitors Price (2020-2025)
3.4 Global C-MET & HGF Inhibitors Industry Company Ranking, 2023 VS 2024 VS 2025
3.5 Global C-MET & HGF Inhibitors Major Company Production Sites & Headquarters
3.6 Global C-MET & HGF Inhibitors Company, Product Type & Application
3.7 Global C-MET & HGF Inhibitors Company Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global C-MET & HGF Inhibitors Market CR5 and HHI
3.8.2 Global Top 5 and 10 C-MET & HGF Inhibitors Players Market Share by Revenue in 2024
3.8.3 2023 C-MET & HGF Inhibitors Tier 1, Tier 2, and Tier 3
4 C-MET & HGF Inhibitors Regional Status and Outlook

4.1 Global C-MET & HGF Inhibitors Market Size and CAGR by Region: 2020 VS 2024 VS 2031
4.2 Global C-MET & HGF Inhibitors Historic Market Size by Region
4.2.1 Global C-MET & HGF Inhibitors Sales in Volume by Region (2020-2025)
4.2.2 Global C-MET & HGF Inhibitors Sales in Value by Region (2020-2025)
4.2.3 Global C-MET & HGF Inhibitors Sales (Volume & Value), Price and Gross Margin (2020-2025)
4.3 Global C-MET & HGF Inhibitors Forecasted Market Size by Region
4.3.1 Global C-MET & HGF Inhibitors Sales in Volume by Region (2026-2031)
4.3.2 Global C-MET & HGF Inhibitors Sales in Value by Region (2026-2031)
4.3.3 Global C-MET & HGF Inhibitors Sales (Volume & Value), Price and Gross Margin (2026-2031)
5 C-MET & HGF Inhibitors by Application

5.1 C-MET & HGF Inhibitors Market by Application
5.1.1 Hospital
5.1.2 Drug Store
5.2 Global C-MET & HGF Inhibitors Market Size by Application
5.2.1 Global C-MET & HGF Inhibitors Market Size Overview by Application (2020-2031)
5.2.2 Global C-MET & HGF Inhibitors Historic Market Size Review by Application (2020-2025)
5.2.3 Global C-MET & HGF Inhibitors Forecasted Market Size by Application (2026-2031)
5.3 Key Regions Market Size by Application
5.3.1 North America C-MET & HGF Inhibitors Sales Breakdown by Application (2020-2025)
5.3.2 Europe C-MET & HGF Inhibitors Sales Breakdown by Application (2020-2025)
5.3.3 Asia-Pacific C-MET & HGF Inhibitors Sales Breakdown by Application (2020-2025)
5.3.4 South America C-MET & HGF Inhibitors Sales Breakdown by Application (2020-2025)
5.3.5 Middle East and Africa C-MET & HGF Inhibitors Sales Breakdown by Application (2020-2025)
6 Company Profiles

6.1 Exelixis
6.1.1 Exelixis Comapny Information
6.1.2 Exelixis Business Overview
6.1.3 Exelixis C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Exelixis C-MET & HGF Inhibitors Product Portfolio
6.1.5 Exelixis Recent Developments
6.2 Ipsen
6.2.1 Ipsen Comapny Information
6.2.2 Ipsen Business Overview
6.2.3 Ipsen C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Ipsen C-MET & HGF Inhibitors Product Portfolio
6.2.5 Ipsen Recent Developments
6.3 Pfizer
6.3.1 Pfizer Comapny Information
6.3.2 Pfizer Business Overview
6.3.3 Pfizer C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Pfizer C-MET & HGF Inhibitors Product Portfolio
6.3.5 Pfizer Recent Developments
6.4 Novartis
6.4.1 Novartis Comapny Information
6.4.2 Novartis Business Overview
6.4.3 Novartis C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Novartis C-MET & HGF Inhibitors Product Portfolio
6.4.5 Novartis Recent Developments
6.5 Takeda
6.5.1 Takeda Comapny Information
6.5.2 Takeda Business Overview
6.5.3 Takeda C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Takeda C-MET & HGF Inhibitors Product Portfolio
6.5.5 Takeda Recent Developments
6.6 Merck KGaA
6.6.1 Merck KGaA Comapny Information
6.6.2 Merck KGaA Business Overview
6.6.3 Merck KGaA C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Merck KGaA C-MET & HGF Inhibitors Product Portfolio
6.6.5 Merck KGaA Recent Developments
6.7 Merck
6.7.1 Merck Comapny Information
6.7.2 Merck Business Overview
6.7.3 Merck C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Merck C-MET & HGF Inhibitors Product Portfolio
6.7.5 Merck Recent Developments
6.8 Daiichi Sankyo
6.8.1 Daiichi Sankyo Comapny Information
6.8.2 Daiichi Sankyo Business Overview
6.8.3 Daiichi Sankyo C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Daiichi Sankyo C-MET & HGF Inhibitors Product Portfolio
6.8.5 Daiichi Sankyo Recent Developments
6.9 GSK
6.9.1 GSK Comapny Information
6.9.2 GSK Business Overview
6.9.3 GSK C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.9.4 GSK C-MET & HGF Inhibitors Product Portfolio
6.9.5 GSK Recent Developments
6.10 Bristol-Myers Squibb(BMS)
6.10.1 Bristol-Myers Squibb(BMS) Comapny Information
6.10.2 Bristol-Myers Squibb(BMS) Business Overview
6.10.3 Bristol-Myers Squibb(BMS) C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Bristol-Myers Squibb(BMS) C-MET & HGF Inhibitors Product Portfolio
6.10.5 Bristol-Myers Squibb(BMS) Recent Developments
6.11 Roche
6.11.1 Roche Comapny Information
6.11.2 Roche Business Overview
6.11.3 Roche C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Roche C-MET & HGF Inhibitors Product Portfolio
6.11.5 Roche Recent Developments
6.12 AVEO Pharmaceuticals
6.12.1 AVEO Pharmaceuticals Comapny Information
6.12.2 AVEO Pharmaceuticals Business Overview
6.12.3 AVEO Pharmaceuticals C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.12.4 AVEO Pharmaceuticals C-MET & HGF Inhibitors Product Portfolio
6.12.5 AVEO Pharmaceuticals Recent Developments
6.13 Amgen
6.13.1 Amgen Comapny Information
6.13.2 Amgen Business Overview
6.13.3 Amgen C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Amgen C-MET & HGF Inhibitors Product Portfolio
6.13.5 Amgen Recent Developments
6.14 AstraZeneca
6.14.1 AstraZeneca Comapny Information
6.14.2 AstraZeneca Business Overview
6.14.3 AstraZeneca C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.14.4 AstraZeneca C-MET & HGF Inhibitors Product Portfolio
6.14.5 AstraZeneca Recent Developments
6.15 Mirati Therapeutics
6.15.1 Mirati Therapeutics Comapny Information
6.15.2 Mirati Therapeutics Business Overview
6.15.3 Mirati Therapeutics C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Mirati Therapeutics C-MET & HGF Inhibitors Product Portfolio
6.15.5 Mirati Therapeutics Recent Developments
6.16 Eli Lilly
6.16.1 Eli Lilly Comapny Information
6.16.2 Eli Lilly Business Overview
6.16.3 Eli Lilly C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.16.4 Eli Lilly C-MET & HGF Inhibitors Product Portfolio
6.16.5 Eli Lilly Recent Developments
6.17 Johnson & Johnson
6.17.1 Johnson & Johnson Comapny Information
6.17.2 Johnson & Johnson Business Overview
6.17.3 Johnson & Johnson C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.17.4 Johnson & Johnson C-MET & HGF Inhibitors Product Portfolio
6.17.5 Johnson & Johnson Recent Developments
6.18 Eisai
6.18.1 Eisai Comapny Information
6.18.2 Eisai Business Overview
6.18.3 Eisai C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.18.4 Eisai C-MET & HGF Inhibitors Product Portfolio
6.18.5 Eisai Recent Developments
6.19 Hutchison MediPharma
6.19.1 Hutchison MediPharma Comapny Information
6.19.2 Hutchison MediPharma Business Overview
6.19.3 Hutchison MediPharma C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.19.4 Hutchison MediPharma C-MET & HGF Inhibitors Product Portfolio
6.19.5 Hutchison MediPharma Recent Developments
6.20 Kringle Pharmaceuticals
6.20.1 Kringle Pharmaceuticals Comapny Information
6.20.2 Kringle Pharmaceuticals Business Overview
6.20.3 Kringle Pharmaceuticals C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.20.4 Kringle Pharmaceuticals C-MET & HGF Inhibitors Product Portfolio
6.20.5 Kringle Pharmaceuticals Recent Developments
7 North America by Country

7.1 North America C-MET & HGF Inhibitors Sales by Country
7.1.1 North America C-MET & HGF Inhibitors Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.1.2 North America C-MET & HGF Inhibitors Sales by Country (2020-2025)
7.1.3 North America C-MET & HGF Inhibitors Sales Forecast by Country (2026-2031)
7.2 North America C-MET & HGF Inhibitors Market Size by Country
7.2.1 North America C-MET & HGF Inhibitors Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.2.2 North America C-MET & HGF Inhibitors Market Size by Country (2020-2025)
7.2.3 North America C-MET & HGF Inhibitors Market Size Forecast by Country (2026-2031)
8 Europe by Country

8.1 Europe C-MET & HGF Inhibitors Sales by Country
8.1.1 Europe C-MET & HGF Inhibitors Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.1.2 Europe C-MET & HGF Inhibitors Sales by Country (2020-2025)
8.1.3 Europe C-MET & HGF Inhibitors Sales Forecast by Country (2026-2031)
8.2 Europe C-MET & HGF Inhibitors Market Size by Country
8.2.1 Europe C-MET & HGF Inhibitors Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.2.2 Europe C-MET & HGF Inhibitors Market Size by Country (2020-2025)
8.2.3 Europe C-MET & HGF Inhibitors Market Size Forecast by Country (2026-2031)
9 Asia-Pacific by Country

9.1 Asia-Pacific C-MET & HGF Inhibitors Sales by Country
9.1.1 Asia-Pacific C-MET & HGF Inhibitors Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.1.2 Asia-Pacific C-MET & HGF Inhibitors Sales by Country (2020-2025)
9.1.3 Asia-Pacific C-MET & HGF Inhibitors Sales Forecast by Country (2026-2031)
9.2 Asia-Pacific C-MET & HGF Inhibitors Market Size by Country
9.2.1 Asia-Pacific C-MET & HGF Inhibitors Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.2.2 Asia-Pacific C-MET & HGF Inhibitors Market Size by Country (2020-2025)
9.2.3 Asia-Pacific C-MET & HGF Inhibitors Market Size Forecast by Country (2026-2031)
10 South America by Country

10.1 South America C-MET & HGF Inhibitors Sales by Country
10.1.1 South America C-MET & HGF Inhibitors Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.1.2 South America C-MET & HGF Inhibitors Sales by Country (2020-2025)
10.1.3 South America C-MET & HGF Inhibitors Sales Forecast by Country (2026-2031)
10.2 South America C-MET & HGF Inhibitors Market Size by Country
10.2.1 South America C-MET & HGF Inhibitors Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.2.2 South America C-MET & HGF Inhibitors Market Size by Country (2020-2025)
10.2.3 South America C-MET & HGF Inhibitors Market Size Forecast by Country (2026-2031)
11 Middle East and Africa by Country

11.1 Middle East and Africa C-MET & HGF Inhibitors Sales by Country
11.1.1 Middle East and Africa C-MET & HGF Inhibitors Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.1.2 Middle East and Africa C-MET & HGF Inhibitors Sales by Country (2020-2025)
11.1.3 Middle East and Africa C-MET & HGF Inhibitors Sales Forecast by Country (2026-2031)
11.2 Middle East and Africa C-MET & HGF Inhibitors Market Size by Country
11.2.1 Middle East and Africa C-MET & HGF Inhibitors Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.2.2 Middle East and Africa C-MET & HGF Inhibitors Market Size by Country (2020-2025)
11.2.3 Middle East and Africa C-MET & HGF Inhibitors Market Size Forecast by Country (2026-2031)
12 Value Chain and Sales Channels Analysis

12.1 C-MET & HGF Inhibitors Value Chain Analysis
12.1.1 C-MET & HGF Inhibitors Key Raw Materials
12.1.2 Key Raw Materials Price
12.1.3 Raw Materials Key Suppliers
12.1.4 Manufacturing Cost Structure
12.1.5 C-MET & HGF Inhibitors Production Mode & Process
12.2 C-MET & HGF Inhibitors Sales Channels Analysis
12.2.1 Direct Comparison with Distribution Share
12.2.2 C-MET & HGF Inhibitors Distributors
12.2.3 C-MET & HGF Inhibitors Customers
13 Concluding Insights
14 Appendix

14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings